stockportfolio.pro
Tandem Diabetes Care, Inc. (TNDM)
Healthcare · Medical Devices · NasdaqGM
Tandem Diabetes Care, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $84.25M | $107.60M | $183.87M | $362.31M | $498.83M | $702.80M | $801.22M | $747.72M | $940.20M | $1.01B |
| Gross profit | $23.59M | $44.09M | $89.82M | $194.21M | $260.52M | $376.21M | $412.99M | $367.69M | $489.57M | $546.01M |
| Net income | $-83.45M | $-73.03M | $-122.61M | $-24.75M | $-34.38M | $15.57M | $-94.59M | $-222.61M | $-96.03M | $-204.71M |
| Net margin | -99.0% | -67.9% | -66.7% | -6.8% | -6.9% | 2.2% | -11.8% | -29.8% | -10.2% | -20.2% |
Source: Tandem Diabetes Care, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Tandem Diabetes Care, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TNDM in your portfolio →
Tandem Diabetes Care, Inc. financial history by metric
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Tandem Diabetes Care, Inc. — frequently asked questions
What is Tandem Diabetes Care, Inc.'s revenue?
Tandem Diabetes Care, Inc. (TNDM) reported revenue of $1.01B for fiscal year 2025, up 7.9% from the prior year, according to its SEC filings.
Is Tandem Diabetes Care, Inc. profitable?
No — TNDM reported a net loss of $-204.71M in fiscal 2025.
What is TNDM's P/E ratio?
Tandem Diabetes Care, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Tandem Diabetes Care, Inc. growing?
TNDM's revenue grew at roughly 15.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Tandem Diabetes Care, Inc. have?
As of fiscal year 2025, TNDM carried roughly $310.04M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Tandem Diabetes Care, Inc.'s gross margin?
TNDM's gross margin was 53.8% in fiscal 2025 — gross profit of $546.01M on revenue of $1.01B.
What is Tandem Diabetes Care, Inc.'s market cap?
Tandem Diabetes Care, Inc. (TNDM) has a market capitalization of about $1.10B, based on the latest data in our nightly-refreshed cache.
When does Tandem Diabetes Care, Inc.'s fiscal year end?
TNDM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Tandem Diabetes Care, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.